MOTS-c Safety Profile
Safety overview of MOTS-c, a mitochondrial-derived peptide with limited human data and no FDA approval.
Last updated: February 12, 2026
For Educational Purposes Only
This safety information is compiled from clinical trial data and regulatory documents for educational purposes. It is not a substitute for professional medical advice. Always consult your healthcare provider about medication safety, especially regarding your individual circumstances, medical history, and other medications.
Safety Overview
MOTS-c is not FDA-approved for any medical use. It is a 16-amino acid peptide naturally encoded in the mitochondrial genome and found in human cells. While this endogenous origin provides a theoretical safety advantage, exogenous administration has not been well-studied in humans.
Evidence Level: Early-stage research with very limited human data. Small clinical trials are in progress but have not published comprehensive safety results.
What We Don’t Know
| Unknown Factor | Why It Matters |
|---|---|
| Optimal dosing range | No established human dosing protocols exist |
| Long-term effects | No studies beyond a few weeks in humans |
| Drug interactions | Activates AMPK pathway — potential interactions with diabetes medications |
| Effects in disease states | Safety unclear in metabolic disorders, cancer, or mitochondrial diseases |
| Injection site tolerance | Limited reporting of local reactions |
Known Mechanism and Theoretical Risks
AMPK Pathway Activation
MOTS-c activates AMP-activated protein kinase (AMPK), a master regulator of cellular energy metabolism. This mechanism overlaps with metformin and other metabolic drugs.
Theoretical concerns:
- Hypoglycemia if combined with diabetes medications
- Interference with cancer treatments (AMPK activation can have context-dependent effects on tumor growth)
- Unknown effects on mitochondrial homeostasis with chronic exogenous dosing
Endogenous vs. Exogenous Administration
While MOTS-c is naturally produced in cells, injecting supraphysiological doses may not replicate endogenous signaling patterns. The body’s response to pharmacological levels is unknown.
Contraindications and Warnings
Due to lack of safety data, MOTS-c should be avoided in:
- Pregnancy and breastfeeding (no data)
- Individuals with diabetes taking glucose-lowering medications (AMPK activation may cause hypoglycemia)
- Active cancer (theoretical AMPK-related concerns)
- Children and adolescents (no pediatric data)
Product Quality Risks
MOTS-c is available from research chemical suppliers and compounding pharmacies, but is not regulated as a pharmaceutical product. Risks include:
- Variable peptide purity and concentration
- Bacterial contamination in poorly manufactured products
- Mislabeling or substitution with other peptides
- No quality assurance or batch testing
Reported Experiences
Anecdotal reports from research use suggest MOTS-c is generally well-tolerated at doses between 5-15 mg, with few immediate adverse effects. However, anecdotal reports are not a substitute for clinical safety data.
This article is for informational purposes only. MOTS-c is not approved for human use. Consult a qualified healthcare provider before using any experimental peptide.
Safety Alerts
Get notified about new safety data, FDA decisions, and adverse event reports.
No spam. Unsubscribe anytime.
Important: Safety information evolves as post-marketing data accumulates. This page reflects data available as of the last update date. Check official FDA and EMA resources for the most current safety information. This content is not intended to diagnose, treat, cure, or prevent any disease.